Design Therapeutics (DSGN) Gains from Investment Securities (2020 - 2026)
Design Therapeutics recorded quarterly Gains from Investment Securities of $132917.0 in Q1 2026, down 99.03% quarter-over-quarter from $13.8 million in Q4 2025, and down 99.01% year-over-year from $13.5 million in Q1 2025.
Design Therapeutics' Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $132917.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 99.01% year-over-year to $132917.0; the TTM figure through Mar 2026 stood at $132917.0 (down 99.01% YoY), while the FY2025 annual figure was $13.8 million, up 33.21% from the prior year.
- Gains from Investment Securities came in at $132917.0 for Q1 2026 at Design Therapeutics, down from $13.8 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $13.9 million in Q3 2025 to a low of $10000.0 in Q2 2022.
- A 5-year average of $6.7 million and a median of $8.0 million in 2023 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities surged 80030.73% in 2023 and tumbled 99.01% in 2026, its largest moves.
- Design Therapeutics' Gains from Investment Securities stood at $5.4 million in 2022, then jumped by 58.65% to $8.6 million in 2023, then rose by 20.63% to $10.3 million in 2024, then soared by 33.21% to $13.8 million in 2025, then slumped by 99.03% to $132917.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $132917.0, $13.8 million, and $13.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132,917.00 |
| Mar 31, 2026 | 132,917.00 |
| Dec 31, 2025 | 13.76 Mn |
| Dec 31, 2025 | 13.76 Mn |
| Sep 30, 2025 | 13.86 Mn |
| Sep 30, 2025 | 13.86 Mn |
| Jun 30, 2025 | 13.78 Mn |
| Jun 30, 2025 | 13.78 Mn |
| Mar 31, 2025 | 13.46 Mn |
| Mar 31, 2025 | 13.46 Mn |
| Dec 31, 2024 | 10.33 Mn |
| Dec 31, 2024 | 10.33 Mn |
| Sep 30, 2024 | 10.63 Mn |
| Sep 30, 2024 | 10.63 Mn |
| Jun 30, 2024 | 466,750.00 |
| Jun 30, 2024 | 466,750.00 |
| Mar 31, 2024 | 328,082.00 |
| Mar 31, 2024 | 328,082.00 |
| Dec 31, 2023 | 8.56 Mn |
| Dec 31, 2023 | 8.56 Mn |
| Sep 30, 2023 | 9.11 Mn |
| Sep 30, 2023 | 9.11 Mn |
| Jun 30, 2023 | 8.01 Mn |
| Jun 30, 2023 | 8.01 Mn |
| Mar 31, 2023 | 60,855.00 |
| Mar 31, 2023 | 60,855.00 |
| Dec 31, 2022 | 5.40 Mn |
| Dec 31, 2022 | 5.40 Mn |
| Sep 30, 2022 | 181,180.00 |
| Sep 30, 2022 | 181,180.00 |
| Jun 30, 2022 | 10,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Mar 31, 2022 | 5.06 Mn |
| Mar 31, 2022 | 5.06 Mn |
| Dec 31, 2021 | 2.67 Mn |
| Dec 31, 2021 | 2.67 Mn |
| Dec 31, 2020 | 1.60 Mn |
| Dec 31, 2020 | 1.60 Mn |